FDA/CDC
FDA/CDC
FDA panel unanimously endorses lecanemab for Alzheimer’s
An intravenous infusion targeting amyloid-beta, lecanemab received accelerated FDA approved earlier in 2023 for the treatment of early Alzheimer’s...
FDA/CDC
CMS to cover Alzheimer’s drugs after traditional FDA okay
“If the FDA grants traditional approval, CMS is prepared to ensure anyone with Medicare Part B who meets the criteria is covered.”
News from the FDA/CDC
FDA approves buprenorphine injection for opioid use disorder
Brixadi is approved in both weekly and monthly subcutaneous injectable formulations at varying doses.
FDA/CDC
FDA approves first drug to treat Alzheimer’s agitation
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease.”
News from the FDA/CDC
FDA moves to stop the spread of illicit ‘tranq’ in the U.S.
The agency “remains concerned about the increasing prevalence of xylazine mixed with illicit drugs,” said FDA Commissioner Robert M. Califf, MD....
FDA/CDC
What to know about newly approved Alzheimer’s drug
The drug has shown moderate positive effects in clinical trials in slowing early...
FDA/CDC
FDA approves second antiamyloid for Alzheimer’s disease
Like its controversial cousin aducanumab, lecanemab was approved under the FDA’s accelerated approval pathway.
FDA/CDC
FDA considers regulating CBD products
The products can have drug-like effects on the body and contain CBD (cannabidiol) and THC (tetrahydrocannabinol).
News from the FDA/CDC
FDA puts REMS requirements on hold to ensure continuity of care
The FDA said it will temporarily not object if inpatient pharmacies dispense a days’ supply of clozapine that aligns with a patient’s monitoring...
Latest News
Eighty percent of U.S. maternal deaths are preventable: Study
“It’s significant. It’s staggering. It’s heartbreaking.”
FDA/CDC
FDA approves ‘rapid-acting’ oral drug for major depression
It is the "first and only rapid-acting oral medicine approved for the treatment of MDD.